Observational cohort studies compare long-term vaccine effectiveness of 2 and 3 doses against HPV infections, suggesting strong protection.
We demonstrated high VE against incident and persistent HPV16 and HPV18 infections up to 14 years after a 3-dose schedule, with no signs of waning and significant indirect effects. Comparable high VEs were found for the 2-dose schedule up to 9 years. Both schedules showed cross-protective effects against persistent HPV31 and HPV45 during prolonged follow-up.
No takes yet. Share an insight, caveat, or question.
Middeldorp et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: